Sökning: WFRF:(Colleoni Marco)
> (2005-2009)
> Forbes John F >
Is chemotherapy nec...
Is chemotherapy necessary for premenopausal women with lower-risk node-positive, endocrine responsive breast cancer? 10-year update of International Breast Cancer Study Group Trial 11-93.
-
Thürlimann, Beat (författare)
-
Price, Karen N (författare)
-
Gelber, Richard D (författare)
-
visa fler...
-
- Holmberg, Stig B, 1946 (författare)
- Gothenburg University,Göteborgs universitet,Institutionen för kliniska vetenskaper, Avdelningen för kirurgi,Institute of Clinical Sciences, Department of Surgery
-
Crivellari, Diana (författare)
-
Colleoni, Marco (författare)
-
Collins, John (författare)
-
Forbes, John F (författare)
-
Castiglione-Gertsch, Monica (författare)
-
Coates, Alan S (författare)
-
Goldhirsch, Aron (författare)
-
- Wallgren, Arne, 1940 (författare)
- Gothenburg University,Göteborgs universitet,Institutionen för kliniska vetenskaper, Avdelningen för onkologi,Institute of Clinical Sciences, Department of Oncology
-
visa färre...
-
(creator_code:org_t)
- 2008-02-08
- 2009
- Engelska.
-
Ingår i: Breast cancer research and treatment. - : Springer Science and Business Media LLC. - 1573-7217 .- 0167-6806. ; 113:1, s. 137-44
- Relaterad länk:
-
https://europepmc.or...
-
visa fler...
-
https://gup.ub.gu.se...
-
https://doi.org/10.1...
-
visa färre...
Abstract
Ämnesord
Stäng
- INTRODUCTION: International Breast Cancer Study Group (IBCSG) Trial 11-93 is the largest trial evaluating the role of the addition of chemotherapy to ovarian function suppression/ablation (OFS) and tamoxifen in premenopausal patients with endocrine-responsive early breast cancer. METHODS: IBCSG Trial 11-93 is a randomized trial comparing four cycles of adjuvant chemotherapy (AC: doxorubicin or epirubicin, plus cyclophosphamide) added to OFS and 5 years of tamoxifen versus OFS and tamoxifen without chemotherapy in premenopausal patients with node-positive, endocrine-responsive early breast cancer. There were 174 patients randomized from May 1993 to November 1998. The trial was closed before the target accrual was reached due to low accrual rate. RESULTS: Patients randomized tended to have lower risk node-positive disease and the median age was 45. After 10 years median follow up, there remains no difference between the two randomized treatment groups for disease-free (hazard ratio=1.02 (0.57-1.83); P=0.94) or overall survival (hazard ratio=0.97 (0.44-2.16); P=0.94). CONCLUSION: This trial, although small, offers no evidence that AC chemotherapy provides additional disease control for premenopausal patients with lower-risk node-positive endocrine-responsive breast cancer who receive adequate adjuvant endocrine therapy. A large trial is needed to determine whether chemotherapy adds benefit to endocrine therapy for this population.
Ämnesord
- MEDICIN OCH HÄLSOVETENSKAP -- Klinisk medicin -- Cancer och onkologi (hsv//swe)
- MEDICAL AND HEALTH SCIENCES -- Clinical Medicine -- Cancer and Oncology (hsv//eng)
Nyckelord
- Antineoplastic Combined Chemotherapy Protocols
- Breast Neoplasms
- drug therapy
- mortality
- Chemotherapy
- Adjuvant
- Cyclophosphamide
- administration & dosage
- Doxorubicin
- administration & dosage
- Epirubicin
- administration & dosage
- Female
- Follow-Up Studies
- Humans
- Lymph Nodes
- pathology
- Lymphatic Metastasis
- Middle Aged
- Premenopause
- Receptors
- Estrogen
- analysis
- Receptors
- Progesterone
- analysis
- Risk Assessment
- Survival Analysis
- Survivors
- Tamoxifen
- therapeutic use
Publikations- och innehållstyp
- ref (ämneskategori)
- art (ämneskategori)
Hitta via bibliotek
Till lärosätets databas
- Av författaren/redakt...
-
Thürlimann, Beat
-
Price, Karen N
-
Gelber, Richard ...
-
Holmberg, Stig B ...
-
Crivellari, Dian ...
-
Colleoni, Marco
-
visa fler...
-
Collins, John
-
Forbes, John F
-
Castiglione-Gert ...
-
Coates, Alan S
-
Goldhirsch, Aron
-
Wallgren, Arne, ...
-
visa färre...
- Om ämnet
-
- MEDICIN OCH HÄLSOVETENSKAP
-
MEDICIN OCH HÄLS ...
-
och Klinisk medicin
-
och Cancer och onkol ...
- Artiklar i publikationen
-
Breast cancer re ...
- Av lärosätet
-
Göteborgs universitet